Charles River Laboratories Announces Second-Quarter 2016 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Charles River Labs (CRL) PT Raised to $100 at Jefferies
August 4, 2016 10:50 AM EDTJefferies analyst raised his price target on Buy-rated Charles River Labs (NYSE: CRL) to $100.00 (from $94.00) following recent earnings.
commented, "CRL displayed continued strength across all segments. Integration of WIL is underway and should lead to margin leverage from the $17-20M cost synergies. CRL is the pre-clinical CRO "category killer" and continues to drive share gains and revenue growth through comprehensive offerings and a focus on high quality science with benefits to utilization, price, and margin."
The analyst had 4 Key Insights:
1) DSA Outperforms in 1st Quarter with WIL. DSA revenue grew... More
Charles River Labs (CRL) PT, Estimates Raised at Evercore ISI
August 3, 2016 11:08 AM EDTEvercore ISI analyst Ross Muken raised estimates and his price target on Charles River Labs (NYSE: CRL) to $91.50 (from $83.50) but maintained a Hold rating.
Muken commented, "Charles Rivers epic nine quarter run continued (core growth in HSD) as biopharma end market strength remains the main story. Strong demand across the... More
Charles River Laboratories (CRL) Tops Q2 EPS by 10c; Bumps Outlook Higher
August 3, 2016 7:05 AM EDTCharles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.20, $0.10 better than the analyst estimate of $1.10. Revenue for the quarter came in at $434.1 million versus the consensus estimate of $425.08 million.
James C. Foster, Chairman, President and Chief Executive Officer, said, I am very pleased to... More
